FSD Pharma Inc. (NASDAQ: HUGE) entered into an agreement with Tekkfund Capital Corp to structure and assist “with certain business development strategies.”
During the duration of this agreement, the company will pay Tekkfund a monthly fee of around CA$12,500 ($9696,75) as well as monthly issuance of 7,000 Class B subordinate voting shares. The initial duration of the agreement will be 24 months.
In addition, on March 9 FSD Pharma issued Crystal Research Associates 30,000 Class B subordinate voting shares at the closing market price. The issuance was in consideration for the preparation of a research report conducted by Crystal.
Earlier this year the company announced the selling of a cannabis facility for almost $13 million and is currently developing psychedelic-based medicines, such as Lucid-Psych, a proprietary molecule in preclinical stages designed to treat depression.
Photo: Courtesy of Cytonn Photography on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.